Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Universität Zürich has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 distinct examiners and 10 distinct art units, indicating broad distribution across the active prosecution docket with limited art-unit repetition.
PATEL, JAY M is the busiest listed examiner, with 1 pending matter. The absence of a concentrated examiner assignment means that response coordination should account for multiple examination contexts rather than rely on one recurring examiner strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (36%) |
| §103 only | 2 (18%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATEL, JAY M | 1 | 65.0% | +39.6% |
| DEUTSCH, TAYLOR M | 1 | 53.3% | +36.3% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| NGUYEN, SANG H | 1 | 88.7% | +11.6% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 19d overdue |
| 19482653 | VISUALLY CONVEYING FUTURE STATE OF PHYSIOLOGICAL STATE OF PATIENT | PATEL, JAY M | — |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | — |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | — |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | — |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | — |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | — |
| 18264953 | USE OF MARKERS FOUND ON LYMPH NODE METASTATIC SAMPLES FOR THE PROGNOSIS OF BREAST CANCER | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019382 | ANTIMICROBIAL PEPTIDOMIMETICS | KONOPELSKI SNAVEL, SARA ELIZABETH | 8d overdue |
| 19482653 | VISUALLY CONVEYING FUTURE STATE OF PHYSIOLOGICAL STATE OF PATIENT | PATEL, JAY M | — |
| 19138132 | SCAR LIGHT MANIPULATOR | DEUTSCH, TAYLOR M | — |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | — |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | — |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | — |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | — |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 3681 | 1 |
| 3798 | 1 |
| 1623 | 1 |
| 2877 | 1 |
| 1678 | 1 |
| 1657 | 1 |
| 1641 | 1 |
| 1644 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19482653 | VISUALLY CONVEYING FUTURE STATE OF PHYSIOLOGICAL STATE OF PATIENT | PATEL, JAY M | 3681 | §101§103 | Non-Final OA | — | Pending | Nov 07, 2025 |
| 19138132 | SCAR LIGHT MANIPULATOR | DEUTSCH, TAYLOR M | 3798 | §103 | Non-Final OA | — | Pending | Jun 12, 2025 |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | 1623 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | 2877 | §101§102§103 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | 1657 | §101§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | 1641 | §102§112Other | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18264953 | USE OF MARKERS FOUND ON LYMPH NODE METASTATIC SAMPLES FOR THE PROGNOSIS OF BREAST CANCER | OUSPENSKI, ILIA I | 1644 | §103§112 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18039530 | Cyclic Tetrapeptides and Metal Complexes Thereof | NIEBAUER, RONALD T | 1658 | §103 | Final Rejection | — | Pending | May 31, 2023 |
| 18019382 | ANTIMICROBIAL PEPTIDOMIMETICS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §112DP | Final Rejection | 8d overdue | Pending | Feb 02, 2023 |
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 1635 | §102§112 | Final Rejection | 19d overdue | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversität Zürich has 11 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Jay M Patel has the most, with 1 of Universität Zürich's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
